Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification : Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
©2023 The Authors; Published by the American Association for Cancer Research..
PURPOSE: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combination with endocrine therapy. We explored the efficacy of palbociclib in patients with nonbreast solid tumors containing an amplification in CCND1, 2, or 3.
PATIENTS AND METHODS: Patients with tumors containing a CCND1, 2, or 3 amplification and expression of the retinoblastoma protein were assigned to subprotocol Z1B and received palbociclib 125 mg once daily for 21 days of a 28-day cycle. Tumor response was assessed every two cycles.
RESULTS: Forty patients were assigned to subprotocol Z1B; 4 patients had outside assays identifying the CCND1, 2, or 3 amplification and were not confirmed centrally; 3 were ineligible and 2 were not treated (1 untreated patient was also ineligible), leaving 32 evaluable patients for this analysis. There were no partial responses; 12 patients (37.5%) had stable disease as best response. There were seven deaths on study, all during cycle 1 and attributable to disease progression. Median progression-free survival was 1.8 months. The most common toxicities were leukopenia (n = 21, 55%) and neutropenia (n = 19, 50%); neutropenia was the most common grade 3/4 event (n = 12, 32%).
CONCLUSIONS: Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 8 vom: 14. Apr., Seite 1477-1483 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Clark, Amy S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
136601-57-5 |
|---|
| Anmerkungen: |
Date Completed 17.04.2023 Date Revised 21.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-22-2150 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353590940 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353590940 | ||
| 003 | DE-627 | ||
| 005 | 20240121231830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-22-2150 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1266.xml |
| 035 | |a (DE-627)NLM353590940 | ||
| 035 | |a (NLM)36853016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Clark, Amy S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification |b Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2023 | ||
| 500 | |a Date Revised 21.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a PURPOSE: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combination with endocrine therapy. We explored the efficacy of palbociclib in patients with nonbreast solid tumors containing an amplification in CCND1, 2, or 3 | ||
| 520 | |a PATIENTS AND METHODS: Patients with tumors containing a CCND1, 2, or 3 amplification and expression of the retinoblastoma protein were assigned to subprotocol Z1B and received palbociclib 125 mg once daily for 21 days of a 28-day cycle. Tumor response was assessed every two cycles | ||
| 520 | |a RESULTS: Forty patients were assigned to subprotocol Z1B; 4 patients had outside assays identifying the CCND1, 2, or 3 amplification and were not confirmed centrally; 3 were ineligible and 2 were not treated (1 untreated patient was also ineligible), leaving 32 evaluable patients for this analysis. There were no partial responses; 12 patients (37.5%) had stable disease as best response. There were seven deaths on study, all during cycle 1 and attributable to disease progression. Median progression-free survival was 1.8 months. The most common toxicities were leukopenia (n = 21, 55%) and neutropenia (n = 19, 50%); neutropenia was the most common grade 3/4 event (n = 12, 32%) | ||
| 520 | |a CONCLUSIONS: Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a palbociclib |2 NLM | |
| 650 | 7 | |a G9ZF61LE7G |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a CCND1 protein, human |2 NLM | |
| 650 | 7 | |a Cyclin D1 |2 NLM | |
| 650 | 7 | |a 136601-57-5 |2 NLM | |
| 700 | 1 | |a Hong, Fangxin |e verfasserin |4 aut | |
| 700 | 1 | |a Finn, Richard S |e verfasserin |4 aut | |
| 700 | 1 | |a DeMichele, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Edith P |e verfasserin |4 aut | |
| 700 | 1 | |a Zwiebel, James |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaldez, Fernanda I |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a McShane, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Rubinstein, Larry V |e verfasserin |4 aut | |
| 700 | 1 | |a Patton, David |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, P Mickey |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Stanley R |e verfasserin |4 aut | |
| 700 | 1 | |a Copur, Mehmet S |e verfasserin |4 aut | |
| 700 | 1 | |a Kasbari, Samer S |e verfasserin |4 aut | |
| 700 | 1 | |a Thind, Ravneet |e verfasserin |4 aut | |
| 700 | 1 | |a Conley, Barbara A |e verfasserin |4 aut | |
| 700 | 1 | |a Arteaga, Carlos L |e verfasserin |4 aut | |
| 700 | 1 | |a O'Dwyer, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Lyndsay N |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Alice P |e verfasserin |4 aut | |
| 700 | 1 | |a Flaherty, Keith T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 8 vom: 14. Apr., Seite 1477-1483 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:8 |g day:14 |g month:04 |g pages:1477-1483 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-22-2150 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 8 |b 14 |c 04 |h 1477-1483 | ||